Effect of cimetidine in patients with non-ulcer dyspepsia and erosive prepyloric changes.
A double-blind, placebo-controlled trial was performed, using 400-mg cimetidine tablets or placebo twice daily for 4 weeks in 100 patients with non-ulcer dyspepsia (NUD) and erosive prepyloric changes (EPC) grade 2 or 3. Symptomatic assessment was made weekly and endoscopic assessment on completion of the treatment period. Symptomatically, a significant effect of cimetidine versus placebo on epigastric pain/discomfort was recorded after 2 weeks' treatment (p less than 0.05). Endoscopically, there was a significant improvement, according to our grading scale of EPC, in the cimetidine-treated group, as compared to the placebo-treated group (p less than 0.05). On the basis of our findings, patients with NUD and EPC who have epigastric pain/discomfort as a prominent symptom seem to profit from treatment with cimetidine.
D000328:Adult; D002927:Cimetidine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004415:Dyspepsia / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D005753:Gastric Mucosa / Q000473:pathology*; D005756:Gastritis / Q000175:diagnosis / Q000188:drug therapy*; D005773:Gastroscopy; D006801:Humans; D008297:Male; D008875:Middle Aged; D013276:Stomach Ulcer / Q000175:diagnosis*
D002927:Cimetidine